Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 641

Similar articles for PubMed (Select 20945361)

1.

Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.

Matta A, Ralhan R, DeSouza LV, Siu KW.

Mass Spectrom Rev. 2010 Nov-Dec;29(6):945-61. doi: 10.1002/mas.20296. Review.

PMID:
20945361
2.

Biomarker discovery and identification in laser microdissected head and neck squamous cell carcinoma with ProteinChip technology, two-dimensional gel electrophoresis, tandem mass spectrometry, and immunohistochemistry.

Melle C, Ernst G, Schimmel B, Bleul A, Koscielny S, Wiesner A, Bogumil R, Moller U, Osterloh D, Halbhuber KJ, von Eggeling F.

Mol Cell Proteomics. 2003 Jul;2(7):443-52. Epub 2003 Jun 23.

3.

The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.

Amacher DE.

Toxicol Appl Pharmacol. 2010 May 15;245(1):134-42. doi: 10.1016/j.taap.2010.02.011. Epub 2010 Feb 26. Review.

PMID:
20219512
4.

Recent advances in capillary electrophoresis-based proteomic techniques for biomarker discovery.

Fang X, Balgley BM, Lee CS.

Electrophoresis. 2009 Dec;30(23):3998-4007. doi: 10.1002/elps.200900219. Review.

PMID:
19960464
5.

The proteomic advantage: label-free quantification of proteins expressed in bovine milk during experimentally induced coliform mastitis.

Boehmer JL, DeGrasse JA, McFarland MA, Tall EA, Shefcheck KJ, Ward JL, Bannerman DD.

Vet Immunol Immunopathol. 2010 Dec 15;138(4):252-66. doi: 10.1016/j.vetimm.2010.10.004. Epub 2010 Oct 14. Review.

PMID:
21067814
6.

Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography-tandem mass spectrometry.

Matta A, DeSouza LV, Shukla NK, Gupta SD, Ralhan R, Siu KW.

J Proteome Res. 2008 May;7(5):2078-87. doi: 10.1021/pr7007797. Epub 2008 Apr 12.

PMID:
18407684
7.
8.

iTRAQ-multidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy.

Ralhan R, Desouza LV, Matta A, Chandra Tripathi S, Ghanny S, Dattagupta S, Thakar A, Chauhan SS, Siu KW.

J Proteome Res. 2009 Jan;8(1):300-9. doi: 10.1021/pr800501j.

PMID:
19072117
9.

Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.

Fredolini C, Liotta LA, Petricoin EF.

Crit Rev Clin Lab Sci. 2010 May-Jun;47(3):125-38. doi: 10.3109/10408363.2010.503558. Epub 2010 Sep 21. Review.

PMID:
20858067
10.

Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery.

Celis JE, Gromov P, Cabezón T, Moreira JM, Ambartsumian N, Sandelin K, Rank F, Gromova I.

Mol Cell Proteomics. 2004 Apr;3(4):327-44. Epub 2004 Jan 30.

11.

Cancer proteomics: from biomarker discovery to signal pathway profiling.

Bichsel VE, Liotta LA, Petricoin EF 3rd.

Cancer J. 2001 Jan-Feb;7(1):69-78. Review.

PMID:
11269650
12.

Head and neck cancer: proteomic advances and biomarker achievements.

Rezende TM, de Souza Freire M, Franco OL.

Cancer. 2010 Nov 1;116(21):4914-25. doi: 10.1002/cncr.25245. Review.

13.

Proteomics of colorectal cancer: overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers.

Jimenez CR, Knol JC, Meijer GA, Fijneman RJ.

J Proteomics. 2010 Sep 10;73(10):1873-95. doi: 10.1016/j.jprot.2010.06.004. Epub 2010 Jun 23. Review.

PMID:
20601272
14.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
15.

Proteomic approaches to the diagnosis, treatment, and monitoring of cancer.

Wulfkuhle JD, Paweletz CP, Steeg PS, Petricoin EF 3rd, Liotta L.

Adv Exp Med Biol. 2003;532:59-68. Review.

PMID:
12908550
16.

Casting light on molecular events underlying anti-cancer drug treatment: what can be seen from the proteomics point of view?

Kraljevic S, Sedic M, Scott M, Gehrig P, Schlapbach R, Pavelic K.

Cancer Treat Rev. 2006 Dec;32(8):619-29. Epub 2006 Oct 25. Review.

PMID:
17069979
17.

Adapting mass spectrometry-based platforms for clinical proteomics applications: The capillary electrophoresis coupled mass spectrometry paradigm.

Metzger J, Luppa PB, Good DM, Mischak H.

Crit Rev Clin Lab Sci. 2009;46(3):129-52. doi: 10.1080/10408360902805261. Review.

PMID:
19404829
18.

Biomarker discovery in biological fluids.

Gao J, Garulacan LA, Storm SM, Opiteck GJ, Dubaquie Y, Hefta SA, Dambach DM, Dongre AR.

Methods. 2005 Mar;35(3):291-302. Epub 2005 Jan 12.

PMID:
15722225
19.

Biomarker discovery in lung cancer--promises and challenges of clinical proteomics.

Bharti A, Ma PC, Salgia R.

Mass Spectrom Rev. 2007 May-Jun;26(3):451-66. Review.

PMID:
17407130
20.

Pre-analytic saliva processing affect proteomic results and biomarker screening of head and neck squamous carcinoma.

Ohshiro K, Rosenthal DI, Koomen JM, Streckfus CF, Chambers M, Kobayashi R, El-Naggar AK.

Int J Oncol. 2007 Mar;30(3):743-9.

PMID:
17273777
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk